[1] |
Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery disease and risk of myocardial infarction[J]. JAMA, 2014, 312(17): 1754-1763.
doi: 10.1001/jama.2014.14681
pmid: 25369489
|
[2] |
Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice[J]. Am Heart J, 2014, 167(6): 846-852.
doi: 10.1016/j.ahj.2014.03.001
pmid: 24890534
|
[3] |
Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project[J]. Arch Intern Med, 2009, 169(9): 843-850.
doi: 10.1001/archinternmed.2009.50
pmid: 19433695
|
[4] |
Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events[J]. Eur Heart J, 2012, 33(6): 734-744.
doi: 10.1093/eurheartj/ehr331
pmid: 21911339
|
[5] |
Sekizuka H, Akashi YJ, Kawasaki K, Yamauchi M, Musha H. Cystatin C: A better marker to detect coronary artery sclerosis[J]. J Cardiol, 2009, 54(3): 359-367.
doi: 10.1016/j.jjcc.2009.06.003
pmid: 19944310
|
[6] |
Akerblom Å, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: Results from the Platelet Inhibition and Patient Outcomes study[J]. Clin Chem, 2012, 58(1): 190-199.
doi: 10.1373/clinchem.2011.171520
pmid: 22126936
|
[7] |
Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983, 51(3): 606.
doi: 10.1016/s0002-9149(83)80105-2
pmid: 6823874
|
[8] |
Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease[J]. N Engl J Med, 2015, 372(14): 1291-1300.
doi: 10.1056/NEJMoa1415516
URL
|
[9] |
Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study[J]. Eur Heart J, 2006, 27(12): 1408-1415.
doi: 10.1093/eurheartj/ehl040
pmid: 16720691
|
[10] |
Pepine CJ, Ferdinand KC, Shaw LJ, et al. Emergence of nonobstructive coronary artery disease: A woman's problem and need for change in definition on angiography[J]. J Am Coll Cardiol, 2015, 66(17): 1918-1933.
doi: 10.1016/j.jacc.2015.08.876
pmid: 26493665
|
[11] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 缺血伴非阻塞性冠状动脉疾病诊断及管理中国专家共识[J]. 中华心血管病杂志, 2022, 50(12):1148-1160.
|
[12] |
Chow BJ, Small G, Yam Y, et al. Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) registry[J]. Arterioscler Thromb Vasc Biol, 2015, 35(4): 981-989.
doi: 10.1161/ATVBAHA.114.304351
pmid: 25676000
|
[13] |
Košuta D, Jug B, Fras Z. Prognostic impact of nonobstructive coronary artery disease detected by coronary computed tomographic angiography[J]. Angiology, 2021, 72(8): 749-753.
doi: 10.1177/0003319721999494
URL
|
[14] |
Liu J, Sukhova GK, Sun JS, et al. Lysosomal cysteine proteases in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2004, 24(8): 1359-1366.
doi: 10.1161/01.ATV.0000134530.27208.41
pmid: 15178558
|
[15] |
Schulte S, Sun J, Libby P, et al. Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice[J]. Am J Pathol, 2010, 177(1): 456-463.
doi: 10.2353/ajpath.2010.090381
pmid: 20472891
|
[16] |
Koc M, Batur MK, Karaarslan O, et al. Clinical utility of serum cystatin C in predicting coronary artery disease[J]. Cardiol J, 2010, 17(4): 374-380.
pmid: 20690093
|
[17] |
Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome[J]. Clin Biochem, 2012, 45(7-8): 535-540.
doi: 10.1016/j.clinbiochem.2012.02.012
pmid: 22394460
|
[18] |
Silva D, Cortez-Dias N, Jorge C, et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction[J]. Am J Cardiol, 2012, 109(10): 1431-1438.
doi: 10.1016/j.amjcard.2012.01.356
pmid: 22356795
|
[19] |
Imai A, Komatsu S, Ohara T, et al. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography[J]. Atherosclerosis, 2011, 218(2): 350-355.
doi: 10.1016/j.atherosclerosis.2011.06.046
pmid: 21782177
|
[20] |
Bairey MCN, Pepine CJ, Walsh MN, et al. Ischemia and no obstructive coronary artery disease (INOCA): Developing evidence-based therapies and research agenda for the next decade[J]. Circulation, 2017, 135(11): 1075-1092.
doi: 10.1161/CIRCULATIONAHA.116.024534
pmid: 28289007
|
[21] |
Kong M, Liu F, Zhu Z. Analysis between high risk of myocardial infarction with non-obstructive coronary artery disease in single center and occurrence of major adverse cardiovascular events[J]. Ann Noninvasive Electrocardiol, 2022, 27(6): e13007.
|
[22] |
Perera D, Berry C, Hoole SP, et al. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: A consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership[J]. Heart, 2022, 109(2):88-95.
doi: 10.1136/heartjnl-2021-320718
pmid: 35318254
|
[23] |
Rajai N, Ahmad A, Toya T, et al. Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease (NOCAD)[J]. Eur J Prev Cardiol, 2022, 30(3):209-216.
doi: 10.1093/eurjpc/zwac184
pmid: 35989450
|